Abingdon, UK, 25th April 2012, OBS Medical Ltd, a world leader in innovative software solutions for the improvement of patients’ lives in the hospital, at home, and through industry with advanced clinical solutions for new drug development, is pleased to announce the following change to the Board of Directors.
Abingdon, UK, 17th April 2012, OBS Medical Ltd, a world leader in innovative software solutions for the improvement of patients’ lives in the hospital, at home, and through industry with advanced clinical solutions for new drug development, is pleased to announce the following changes to the Board of Directors.
OBS Medical are pleased to announce the release of Visensia 3.3. This is a new release with some enhancements. Users of previous releases are encouraged to upgrade. Please “read more” for the full details of the release.
Spaulding Clinical Selects BioQT™ for use with the Spaulding IQ™ ECG System and Phase 1 Clinical Pharmacology Unit
OBS Medical will be demonstrating BioQT, the future for Automated QT Analysis at the Cardiovascular Risk Assessment Summit. For more information come and meet us on the booth to discover the benefits BioQT can bring to your drug development trials.
OBS Medical is pleased to announce that it has successfully signed an agreement with a leading Clinical Research Organisation to use BioQT for their Thorough QT analysis trials.
A top 5 global Clinical Research Organisation has requested the opportunity to evaluate BioQT with the view to use for automated QT analysis requirements. This is based on a growing demand from the pharmaceutical industry that is recognising the benefits which can be gained from this technology.
BioQT is to be evaluated by leading global pharmaceutical company. Results to be released in 2012.
OBS Medical Ltd, the patient monitoring systems company, is pleased to announce the following changes to the Board of Directors.
Richard Moon, Chairman and Non-Executive Director and Allan Cockell, Non-Executive Director, are retiring from Board with immediate effect.
OBS Medical Ltd, today announced that Visensia has received 510k clearance from the FDA. This is the fourth 510k clearance for Visensia since the original introduction of Visensia (Originally known as BioSignTM) in 2005. Visensia was the first FDA cleared patient health index device with alerts on the market and is continuing to develop innovative leading edge products.
OBS Medical and t+ Medical Ltd presents the project Help4Mood, a significant advance in supporting the recovery of people with major depression at home. The project is funded by the European Union’s Seventh Framework Programme, has a budget of around 3 million euros.
OBS will be attending the following trade shows this year:
OBS Medical Celebrates 10 Years of Business
These companies with origins in Oxford University, have come together in a long anticipated merger
Radio and website Interviews with the team at Oxford who are using t+ blood pressure lite.